BioAlliance Pharma’s (Euronext Paris –BIO) Board has approved the draft resolutions on Board changes, to be voted at the General Assembly Meeting on June 29, 2011.
Following Mr. André Ulmann and Mr. Gilles Marrache expressed wishes not to pursue their board mandate due to personal constraints, the Board thanks them for their commitment and contribution to its work and will propose their replacement at next General Assembly Meeting respectively by the company Financière de la Montagne, the first BioAlliance’s shareholder, represented by Mr. Nicolas Trebouta, and by Mr. David Solomon.
Moreover, the Board will propose the ratification of Mr. Patrick Langlois cooptation as new board member as well as the nomination of Mrs. Judith Greciet, presently Chief Operating Officer of BioAlliance Pharma.
The Board of Directors will then comprise 9 members, including 4 new administrators.
Besides, the Board intends to appoint Patrick Langlois as its new President after André Ulmann’s resignation following the General Assembly.
« Considering BioAlliance’s challenges, I have proposed the cooptation of Patrick Langlois for its expertise in corporate development, and the nomination of two other members, first to reinforce shareholders’ representation at the Board and secondly to enrich the group with international visions, specially Anglo-Saxon culture”, commented André Ulmann.
Patrick Langlois, Ph. D. in Economics and Finance, started his career at Louis Dreyfus bank and pursued most of his career at Rhône-Poulenc and Aventis SA as Executive Vice President and CFO. He currently is General Partner of PJL Conseil. He also serves as board member and non Executive Director of several biopharmaceutical companies in Europe and in the United-States, notably Shire plc, Newron Pharmaceuticals, Innate Pharma, Exonhit Therapeutics. His expertise in corporate development and mergers and acquisitions in the biotech and pharmaceutical areas will be a major input for the company’s development.
Nicolas Trebouta, MD, via his company Financière de la Montagne, has been since 2004 investing in biotechnology companies, directly or through funds. He has co-founded Chevrillon et Associé in 2000 and through this structure has achieved several LBO such as Picard (frozen food), CPI (printing company) or Alingia (insurance company). He is a medical doctor and shareholder of BioAlliance Pharma since 2008.
David H. Solomon, MD, serves as CEO of Zealand Pharma (Denmark). He has extensive experience in pharmacology research, having served as faculty member at Columbia University’s College of Physicians and Surgeons in New York, NY as well as leadership positions at several biotechnology, pharmaceutical and medical device companies. From 2003-2006, Dr. Solomon led healthcare investing at Carrot Capital Healthcare Ventures.